Gossamer Bio shares crash after lung disease drug fails late stage trial

Gossamer Bio shares crashed 80% today after its lung drug failed a late-stage trial. The firm still plans to discuss the results with federal regulators.

Insights:
Gossamer Bio, Inc. , a biotechnology firm based in the United States USUS, reported on February 23, 2026, that its lead program, the inhaled investigational drug seralutinib, failed to meet the primary efficacy threshold in a late-stage (pivotal) trial. The study was designed to treat pulmonary arterial hypertension, but it did not achieve the statistical threshold for improving the six-minute walking distance (the trial's primary endpoint). This trial failure directly affects the development and regulatory prospects of Gossamer's lead program.
FILE PHOTO: A general view of a room at the Ulm Bundeswehr hospital in Ulm, Germany, on March 24, 2020, as preparations are made for the admission of patients during the COVID-19 pandemic. REUTERS/Andreas Gebert/File Photo
FILE PHOTO: A general view of a room at the Ulm Bundeswehr hospital in Ulm, Germany, on March 24, 2020, as preparations are made for the admission of patients during the COVID-19 pandemic. REUTERS/Andreas Gebert/File Photo